As part of its StrategiesPlus COVID-19 ACT program, each division of the company will provide specialized expertise to help develop safe, effective treatments. It offers the following:

• Mechanistic GastroPlus pulmonary simulations to investigate alternative dosing modalities and optimize dosing to target lung exposure
• Application of GastroPlus modeling and simulation data in regulatory reports to support repurposing strategies or drug product quality claims
• Utilization of quantitative systems toxicology and pharmacology models from drug-induced liver injury modeling software to predict potential liver toxicity risk, efficacy potential for pulmonary injury-related pathophysiology, or efficacy potential for cardiac injury-related pathophysiology of drug candidate treatments for COVID-19
• Semi-mechanistic drug and disease modeling and simulation support, including implementation of viral dynamics models for clinical and strategic decision-making and regulatory submissions
• Comprehensive clinical pharmacology consulting for drug development and regulatory interaction